Interstitial Lung DiseaseREPRO-PIDNCT06743022
Evaluation of the Reproducibility of the Automated Measurement of the Extent of ILD on Chest CT
A study testing Chest CT in people with Interstitial Lung Disease, run by Assistance Publique - Hôpitaux de Paris at 6 sites in France.
Trial summary
In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. Automated tools are now available to quantify ILD, but there is a lack of data on the reproducibility of this measurement and therefore its accuracy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Interstitial Lung Disease
- What is being tested?
- Chest CT
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 6 sitesFrance
- Study dates
- 24 Jun 2025to Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Known interstitial lung disease as part of idiopathic pulmonary fibrosis or connective tissue disease
- Followed in one of the participating hospitals
- Requiring a chest CT as part of a scheduled assessment
- Affiliated to a French national social security
- Informed consent
Who cannot join
- Acute exacerbation of ILD
- Pregnancy
- Inability to hold an apnea for 10 seconds
- Patients in the exclusion period after a previous research
- Need for additional procubitus or expiratory images
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
6 sites in 1 country
France6 sites, 6 recruiting
- Recruiting
APHP - Bichat hospital - Radiology
Paris, IDF, 75010
Marie-Pierre DEBRAY, MD, marie-pierre.debray@aphp.fr
- Recruiting
APHP - Bichat hospital - Rheumatology
Paris, IDF, 75010
Pierre-Antoine JUGE, pierre-antoine.juge@aphp.fr
- Recruiting
APHP - Cochin Hospital - Internal medicine
Paris, IDF, 75014
Benjamin CHAIGNE, benjamin.chaigne@aphp.fr
- Recruiting
APHP - Cochin Hospital - Pneumology
Paris, IDF, 75014
Isabelle HONORE, isabelle.honore@aphp.fr
- Recruiting
APHP - Cochin Hospital - Radiology
Paris, IDF, 75014
Guillaume CHASSAGNON, MD, PhD, guillaume.chassagnon@aphp.fr
Marie-Pierre REVEL, MD, PhD
- Recruiting
APHP - Bichat Hospital - Pneumology
Paris, IDF, 75018
Raphaël BORIE, raphael.borie@aphp.fr
Pierre LE GUEN
About this study
Official title: Evaluation of the Reproducibility of the Automated Measurement of the Extent of Interstitial Lung Disease on Chest CT
In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. Automated tools are now available to quantify ILD, but there is a lack of data on the reproducibility of this measurement and therefore its accuracy.
Therefore, the purpose of this study is to evaluate the variability of automated ILD quantification on chest CT. Reproducibility will be assessed by repeating chest CT scans and using different tools to measure the extent of disease.
Read the detailed description
In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. In recent years, several tools based on texture analysis or deep learning methods have been developed to provide rapid and accurate automated quantification of ILD extent.
An advantage of automated scoring methods is that they theoretically offer perfect repeatability of measurement. However, this is only true if the measurement is repeated on the same images. Several parameters can alter the appearance of the lungs on scanner images, such as the degree of inspiration or the reconstruction kernel used to reconstruct the images. There is a lack of data on the reproducibility of the whole process of automated ILD quantification and therefore its accuracy.
Therefore, the purpose of this study is to evaluate the variability of automated ILD quantification on chest CT.
Reproducibility will be assessed by repeating chest CT scans and using different tools to measure the extent of disease in patients with ILD from 2 institutions. Chest CT will be repeated the same day. This will allow assessment of the variability of automated measurement of ILD extent between 2 CT scans performed on the same day and when using different software. It will also allow to assess the variability of lung volume between the 2 CT scans and the effect of disease (idiopathic pulmonary fibrosis or connective tissue disease-related ILD) on the reproducibility of ILD quantification.
- Conditions
- Interstitial Lung Disease
- Being tested
- Chest CT
- Keywords
- Lung Diseases, Interstitial Lung Disease, Multidetector Computed Tomography, Deep Learning
- Medical subject headings
- Lung Diseases, Interstitial, Lung Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chest CTDiagnostic test
Repeated chest CT for automated ILD quantification
| Study group | Role | What they receive |
|---|---|---|
| Patients with interstitial lung disease | Experimental | Not described Receives: Diagnostic Test: Chest CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Automated Interstitial Lung Disease (ILD) quantification
Reproducibility of ILD quantification on chest CT (as a percentage of lung volume) between two successive scan acquisitions.
Measured: Day of inclusion
Secondary outcomes (3)
Automated Interstitial Lung Disease (ILD) quantification
Reproducibility of disease extent measured with different software on the same acquisition
Measured: Day of inclusion
Lung volume
Reproducibility of total lung volume measured on the scanner between two successive acquisitions
Measured: Day of inclusion
Automated Interstitial Lung Disease (ILD) quantification
Reproducibility of disease extension between the two scan acquisitions depending on the disease (idiopathic pulmonary fibrosis or PID secondary to connective tissue disease).
Measured: Day of inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Dec 2024
- Study start24 Jun 2025
- Primary completionAug 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Interstitial Lung DiseaseStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- Responsible party
- Sponsor
- Investigators
- Guillaume CHASSAGNON, MD, PhD, Principal investigator, Cochin Hospital - AP-HP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06743022
- Sponsor's protocol ID
- APHP240783
- Other IDs
- 2024-A01384-43
- Acronym
- REPRO-PID
- Status last verified
- Sep 2026
- First submitted
- 16 Dec 2024
- Last updated
- 22 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Reproducibility of the Automated Measurement of the Extent of Interstitial Lung Disease on Chest CT
- ClinicalTrials.gov ID
- NCT06743022
- Acronym / sponsor ID
- REPRO-PID / APHP240783
- Conditions
- Interstitial Lung Disease
- Keywords
- Lung Diseases, Interstitial Lung Disease, Multidetector Computed Tomography, Deep Learning
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- Study start
- 24 Jun 2025 (actual)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 19 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. Automated tools are now available to quantify ILD, but there is a lack of data on the reproducibility of this measurement and therefore its accuracy.
Therefore, the purpose of this study is to evaluate the variability of automated ILD quantification on chest CT. Reproducibility will be assessed by repeating chest CT scans and using different tools to measure the extent of disease.
Detailed description
In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. In recent years, several tools based on texture analysis or deep learning methods have been developed to provide rapid and accurate automated quantification of ILD extent.
An advantage of automated scoring methods is that they theoretically offer perfect repeatability of measurement. However, this is only true if the measurement is repeated on the same images. Several parameters can alter the appearance of the lungs on scanner images, such as the degree of inspiration or the reconstruction kernel used to reconstruct the images. There is a lack of data on the reproducibility of the whole process of automated ILD quantification and therefore its accuracy.
Therefore, the purpose of this study is to evaluate the variability of automated ILD quantification on chest CT.
Reproducibility will be assessed by repeating chest CT scans and using different tools to measure the extent of disease in patients with ILD from 2 institutions. Chest CT will be repeated the same day. This will allow assessment of the variability of automated measurement of ILD extent between 2 CT scans performed on the same day and when using different software. It will also allow to assess the variability of lung volume between the 2 CT scans and the effect of disease (idiopathic pulmonary fibrosis or connective tissue disease-related ILD) on the reproducibility of ILD quantification.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with interstitial lung disease | Experimental | Diagnostic Test: Chest CT |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥ 18 years
- Known interstitial lung disease as part of idiopathic pulmonary fibrosis or connective tissue disease
- Followed in one of the participating hospitals
- Requiring a chest CT as part of a scheduled assessment
- Affiliated to a French national social security
Key exclusion criteria (5 listed)
- Acute exacerbation of ILD
- Pregnancy
- Inability to hold an apnea for 10 seconds
- Patients in the exclusion period after a previous research
- Need for additional procubitus or expiratory images
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chest CTRepeated chest CT for automated ILD quantification | Diagnostic test | Patients with interstitial lung disease |
Primary outcome
Automated Interstitial Lung Disease (ILD) quantification
Time frame: Day of inclusion
Reproducibility of ILD quantification on chest CT (as a percentage of lung volume) between two successive scan acquisitions.
3 secondary outcomes
Automated Interstitial Lung Disease (ILD) quantification
Time frame: Day of inclusion
Lung volume
Time frame: Day of inclusion
Automated Interstitial Lung Disease (ILD) quantification
Time frame: Day of inclusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Interstitial Lung Disease
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingObservational study
Single-Cell Sequencing Analysis of Radiation Pneumonitis Signals In Patients Treated For Cancer With Radiotherapy
Radiation Pneumonitis
RecruitingPhase 2
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
Fibrotic Interstitial Lung Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Guillaume CHASSAGNON, MD, PhD principal investigator
Cochin Hospital - AP-HP
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chest CT in people with Interstitial Lung Disease, run by Assistance Publique - Hôpitaux de Paris at 6 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Guillaume CHASSAGNON, MD, PhD (+33158414326, guillaume.chassagnon@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Automated Interstitial Lung Disease (ILD) quantification (time frame: Day of inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.